AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

Quanterix Announces the Simoa Accelerator, an Innovation Center for Biomarker Research and Custom Assay Development

Quanterix Announces the Simoa Accelerator, an Innovation Center for Biomarker Research and Custom Assay Development

December 16, 2014

LEXINGTON, Mass.--()--Quanterix Corp

Agios Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

Agios Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

December 16, 2014

CAMBRIDGE, Mass.Dec.

Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors

Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors

December 12, 2014

 CAMBRIDGE, Mass.--()--Acceleron Pharma Inc.

Syros Pharmaceuticals Announces New Research Published on CDK7 in Lung and Pediatric Cancers

Syros Pharmaceuticals Announces New Research Published on CDK7 in Lung and Pediatric Cancers

December 11, 2014

- Papers in Cell and Cancer Cell describe in vivo activity of CDK7 inhibitors; further validate company’s lead preclinical program -

WATERTOWN, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, announced today the recent publication of two studies that further demonstrate the critical role of CDK7 in cancers driven by oncogenic transcription factors, including certain lung and pediatric cancers.

Syros Pharmaceuticals Presents New Data from Its Gene Control Platform at Oncology Conferences

Syros Pharmaceuticals Presents New Data from Its Gene Control Platform at Oncology Conferences

December 11, 2014

- Posters at 56th ASH Annual Meeting and 2014 San Antonio Breast Cancer Symposium highlight identification of patient subtypes and novel drug targets in acute myeloid leukemia and breast cancer -

Concert Pharmaceuticals Names Thomas Auchincloss to Board of Directors and Chair of the Audit Committee

Concert Pharmaceuticals Names Thomas Auchincloss to Board of Directors and Chair of the Audit Committee

December 10, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc

Agios Pharmaceuticals Appoints Kaye Foster-Cheek to its Board of Directors

Agios Pharmaceuticals Appoints Kaye Foster-Cheek to its Board of Directors

December 10, 2014

CAMBRIDGE, Mass.Dec.

Symbiota Appoints International Plant Sciences Leader Dr. Roger Beachy to its Board of Directors

Symbiota Appoints International Plant Sciences Leader Dr. Roger Beachy to its Board of Directors

December 10, 2014

CAMBRIDGE, Mass., December 10, 2014 /PRNewswire/ — Symbiota™, pioneer of plant microbiome solutions that naturally promote plant health and improve agricultural production, today announced the key addition of Dr. Roger Beachy to its board of directors.